id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-2326-0003,FDA,FDA-2014-E-2326,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-03T05:00:00Z,2015,11,2015-11-03T05:00:00Z,,2015-11-03T19:51:51Z,,0,0,0900006481d09b01
FDA-2014-E-2326-0001,FDA,FDA-2014-E-2326,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-01-07T05:00:00Z,2015,1,2015-01-07T05:00:00Z,,2015-01-07T22:33:59Z,,0,0,09000064819ac236
FDA-2014-E-2326-0002,FDA,FDA-2014-E-2326,"Patent Term Extension Application from Finnegan, Henderson, Farabow, Garrett and Dunner, LLP on Behalf of Pierre Fabre Medicament",Other,Application,2015-01-07T05:00:00Z,2015,1,2015-01-07T05:00:00Z,,2015-01-07T22:34:05Z,,0,0,09000064819ac238